StockCIK 1582313
Xenon Pharmaceuticals Inc. (XENE): Insider Trades and Fund Holdings
In the past 12 months, Xenon Pharmaceuticals Inc. insiders reported 2 open-market purchases worth $1.68M and 2 sales worth $1.07M; 1 of the sales were reported as made under a 10b5-1 trading plan.
2Insider buys, 12 months
$1.68MBought by insiders, 12 months
$1.07MSold by insiders, 12 months
2Tracked funds holding
Recent insider trades
Open-market purchases (code P) and sales (code S) from Form 4. Grants, option exercises and gifts are not shown. Latest filing: Oct 1, 2026.
| Filed | Insider | Type | Value |
|---|---|---|---|
| Oct 1 | Ian MortimerCEO | ▲ BUY | $1.12M |
| Oct 1 | Thomas Patrick KellyCFO | ▲ BUY | $560K |
| Aug 31 | Christopher John KenneyChief Medical Officer | ▼ SELL10b5-1 | $426K |
| Aug 13 | Steven GannonDirector | ▼ SELL | $641K |
Source: SEC Form 4 filings, retrieved Oct 28, 2026. How we read filings
Insiders who traded in the past year
| Insider | Role | Buys | Bought | Sells | Sold |
|---|---|---|---|---|---|
| Ian Mortimer | CEO | 1 | $1.12M | 0 | $0 |
| Thomas Patrick Kelly | CFO | 1 | $560K | 0 | $0 |
| Christopher John Kenney | Chief Medical Officer | 0 | $0 | 1 | $426K |
| Steven Gannon | Director | 0 | $0 | 1 | $641K |
ADVERTISEMENT
320 × 100 ad slot
Tracked funds that report XENE
From each fund's latest 13F. Holdings are as of quarter end and are filed up to 45 days later.
| Fund | Shares | Value | Change |
|---|---|---|---|
| Renaissance Technologies | 187,110 | $11.3M | ▼ −37.7% |
| Duquesne Family Office | 238,600 | $14K | No change |
Source: SEC Form 13F-HR filings, retrieved Oct 28, 2026. How we read filings
Reading these numbers
Insiders sell for many reasons: taxes, diversification, a house. Purchases with their own money are rarer and are usually read as more informative. A Form 4 is due within two business days of the trade. How to read a Form 4 →